Best New Life Sciences Company in Scotland 2013 Applications, features and benefits SVOP.

Best New Life Sciences Company in Scotland 2013

Applications, features and benefitsSVOP

The SVOP: An OverviewThe SVOP is a Saccadic Vector Optokinetic

PerimeterThe SVOP is a visual field analyser invented

at the Royal Hospital for Sick Children in Edinburgh, UK and commercialised by i2eye Diagnostics Ltd.

The SVOP was developed to meet a clinical need to screen young children and those unable to perform a standard visual field.

The SVOP is easy and intuitive to use by both patients and operators. It can screen patients from under one year old to over 70

The SVOP produces a standard visual field plot familiar to all eye-care professionals.

How Does the SVOP Work?There is an introductory video to the SVOP on

i2eye’s website at: www.i2eyediagnostics.com The SVOP has an eye-tracker to continuously

monitor the patient’s gaze direction and distance from the instrument. It uses this information to:Confirm their fixation,Accurately place target images within the central

30 degrees of their visual field and,Record their response by tracking their eye

movement as they react to the appearance of the target.

The SVOP Printout

The SVOP Patient BenefitsPatient comfort

Free head movementNo head or chin restNo physical contact with the instrumentSome movement allowed

Concentration benefitsSimple intuitive test, no complex instructionsResponse recorded objectively without considered

feedback from the patientTest normally complete within three minutes

Coverage of Conventional VF’s Conventional

automatic static perimeters can screen approx. 60 % of the population who are aged between 10 and 70 years and are neurologically normal.

Young children, the frail elderly and those with compromised neurological function cannot be screened reliably

Coverage of the SVOP The SVOP can screen

over 85% of the population aged between one and >70 years who are neurologically normal

Infants and the frail elderly can be screened reliably

A proportion of neurologically compromised subjects can be tested

The SVOP AdvantageThe SVOP is a rapid automatic screening test suitable

for >90 % of neurologically normal subjects with normal eyes

The SVOP is suitable for all ages from one to over 70 years

A normal result has a 95% confidence levelAn abnormal or ambiguous result requires further

investigation

Low operator skill (nurse, technician etc)Low patient stress2 minute testCentral 30 degree field

Research HorizonsUnderstand current limitations

•Neurologically intact with normal eyes 95% success•Brain tumours/discreet lesions approx. 50% success•Paediatric stroke approx. 30% success rates•Cerebral palsy <10% success

The patient must engage and calibrate•5-10% of patients will not look at or maintain engagement with the screen•Too few calibration points for accurate tracking

• Eyetracker line of sight blocked – hair, glasses, dry eyes, deep-set eyes

• Abnormal eye does not fit model – switch to KidzEyez or other method

Principal research opportunities•30-50% of neurologically compromised patients give inconsistent results that are not as anticipated•Condition specific normative data, analysis and interpretation necessary to improve performance of SVOP- collaboration, Open Innovation

Screening and testing•Screens 95% of the neurologically healthy population•Rapidly (2 minutes) identifies those who require further investigation•Frees resources to concentrate in areas of need•Ongoing internal and collaborative research is continually improving reach

Research Horizons for the SVOP SVOP is a new

generation of visual function tester.

There are research opportunities to improve its reach into testing severely neurologically compromised individuals

i2eye actively encourages collaborative and third-party research through Open Innovation

Key UsersInstitution Contact role

Boston Children’s Hospital Dr Gena Heidary Director of Neuro-ophthalmology service

Cincinnati Children’s Hospital

Dr Constance West Director of ophthalmology, Associate Professor

Johns Hopkins Hostpital Micheal Repka Professor of Ophthalmology & Pediatrics

Moorfields Eye Hospital Ms Annegret Dahlmann-Noor

Consultant paediatric ophthalmologist

Newcastle eye centre Mr Michael Clarke Consultant paediatric ophthalmologist

Private practice, Paris Dr Eliane DeLouvrier Paediatric ophthalmologist

Ludwig-Maximilians-Universitt

Prof Birgit Lorenz Paediatric ophthalmologist, Head of Department, Chairman.

Dr Gena Heidary Dr Luisa MayerDr Constance West Mr Michael Clarke

Prof. Birgit Lorenz

AvailabilitySVOP is commercially available now in:

Europe (CE marked class 2a medical device)Australia (TGA approved class 2a medical device)USA (FDA listed class 1 medical device exempt from

510(k)SVOP costs (POA) including:

Delivery and training12 month warranty12 month software updates including those that

enhance performance or reach.Email and telephone support

Ongoing maintenance contracts from Euro 1000 per year

Clinical ReferencesVisual Field assessment in infants using Saccadic Vector Optokinetic Perimetry BIPOSA 2013, invited verbal presentation, Brian Fleck

Saccadic Vector Optokinetic Perimetry (SVOP): A novel technique for automated static perimetry in children using eye tracking.Murray I, Perperidis A, Brash H, Cameron L, McTrusty A, Fleck B, Minns R.Conf Proc IEEE Eng Med Biol Soc. 2013;2013:3186-9. doi: 10.1109/EMBC.2013.6610218.PMID: 24110405 [PubMed - in process]

Visual field measurement in infants and young children with neurological disorders using saccadic vector optokinetic perimetry (SVOP).Brian W. Fleck, Ian Murray, Harry Brash, Robert MinnsJournal of AAPOS February 2012 (Vol. 16, Issue 1, Page e5)

Feasibility of saccadic vector optokinetic perimetry: a method of automated static perimetry for children using eye tracking.Murray IC, Fleck BW, Brash HM, Macrae ME, Tan LL, Minns RA.Ophthalmology. 2009 Oct;116(10):2017-26. doi: 10.1016/j.ophtha.2009.03.015. Epub 2009 Jun 27.PMID: 19560207 [PubMed - indexed for MEDLINE]

093: Automated visual field assessment in young children using eye tracking—preliminary data from 9 children Ian C. Murray, Mary E. MacRae, Brian W. Fleck, Harry M. Brash, Lai L. Tan, Robert A. Minns Journal of AAPOS February 2009(Vol. 13, Issue 1,Page e24)

Contact i2eye Diagnostics ltd9 Edinburgh BioQuarterLittle FranceEdinburgh EH16 4UXUK

T: +44 (0) 131 658 5154E: [email protected]: www.i2eyediagnostics.com

In the USASteve Elfrink: [email protected]: 608-632-0914